From world-class science to patient-centered care, the 2022 ASCO Genitourinary (GU) Cancers Symposium offered new, innovative findings in the study, diagnosis, and treatment of GU malignancies.   Catch up on key trials in prostate, bladder and kidney cancer, including findings from the PROpel, ARASENS, and BAYOU studies and more.
View all videos

GU Cancers 2022

ASCO Genitourinary Cancers Symposium
17–19 February 2022 | San Francisco, CA
VJOncologyVJ Oncology@VJOncology·
February 7, 2023

🎥 @WainbergZev of @UCLA talks on daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC

Watch: 👉http://ow.ly/966T50MIV6t👈

@ASCO #GI23 #GastrointestinalCancer #PancSM #PancreaticCancer

Reply on Twitter 1622868161723875328Retweet on Twitter 1622868161723875328Like on Twitter 1622868161723875328Twitter 1622868161723875328
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

🎥 Ken Kato of National Cancer Center Hospital talks on the 29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC

Watch: 👉http://ow.ly/3GZs50MIV3Q👈

@ASCO #GI23 #GastrointestinalCancer #ESOCSM

Reply on Twitter 1622641829299486733Retweet on Twitter 1622641829299486733Like on Twitter 1622641829299486733Twitter 1622641829299486733
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

EGFR exon 20 insertion mutations in #LungCancer - find our how to identify these mutations and manage patients in the UK

2nd March at 6-7pm GMT

ft. @DrSanjayPopat @Anna_Minchom @DrRiyazShah @AlastairGreyst2

Organized by @VJOncology & @BTOGORG

Registration now open!

Reply on Twitter 1622621200093421568Retweet on Twitter 16226212000934215685Like on Twitter 16226212000934215688Twitter 1622621200093421568
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

Want something interesting to read this week?

Why not take a look at some of the feature articles we have over on VJOncology?

We've got the latest updates from across a whole range of disease areas, to keep you informed!

Read here: 📖 https://www.vjoncology.com/features/ 📖

Reply on Twitter 1622566309639729155Retweet on Twitter 1622566309639729155Like on Twitter 1622566309639729155Twitter 1622566309639729155
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

🎥 Heinz Josef Lenz (@HJLenz59) of @USC talks on addressing resistance to ICIs in colorectal cancer

Watch: 👉http://ow.ly/12oo50MIP1g👈

@ASCO #GI23 #GastrointestinalCancer #CRCSM #ColorectalCancer

Reply on Twitter 1622520898484830208Retweet on Twitter 1622520898484830208Like on Twitter 16225208984848302082Twitter 1622520898484830208
Load More

GU Cancers 2022

ASCO Genitourinary Cancers Symposium
17–19 February 2022 | San Francisco, CA
From world-class science to patient-centered care, the 2022 ASCO Genitourinary (GU) Cancers Symposium offered new, innovative findings in the study, diagnosis, and treatment of GU malignancies.   Catch up on key trials in prostate, bladder and kidney cancer, including findings from the PROpel, ARASENS, and BAYOU studies and more.
View all videos
VJOncologyVJ Oncology@VJOncology·
February 7, 2023

🎥 @WainbergZev of @UCLA talks on daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC

Watch: 👉http://ow.ly/966T50MIV6t👈

@ASCO #GI23 #GastrointestinalCancer #PancSM #PancreaticCancer

Reply on Twitter 1622868161723875328Retweet on Twitter 1622868161723875328Like on Twitter 1622868161723875328Twitter 1622868161723875328
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

🎥 Ken Kato of National Cancer Center Hospital talks on the 29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC

Watch: 👉http://ow.ly/3GZs50MIV3Q👈

@ASCO #GI23 #GastrointestinalCancer #ESOCSM

Reply on Twitter 1622641829299486733Retweet on Twitter 1622641829299486733Like on Twitter 1622641829299486733Twitter 1622641829299486733
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

EGFR exon 20 insertion mutations in #LungCancer - find our how to identify these mutations and manage patients in the UK

2nd March at 6-7pm GMT

ft. @DrSanjayPopat @Anna_Minchom @DrRiyazShah @AlastairGreyst2

Organized by @VJOncology & @BTOGORG

Registration now open!

Reply on Twitter 1622621200093421568Retweet on Twitter 16226212000934215685Like on Twitter 16226212000934215688Twitter 1622621200093421568
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

Want something interesting to read this week?

Why not take a look at some of the feature articles we have over on VJOncology?

We've got the latest updates from across a whole range of disease areas, to keep you informed!

Read here: 📖 https://www.vjoncology.com/features/ 📖

Reply on Twitter 1622566309639729155Retweet on Twitter 1622566309639729155Like on Twitter 1622566309639729155Twitter 1622566309639729155
VJOncologyVJ Oncology@VJOncology·
February 6, 2023

🎥 Heinz Josef Lenz (@HJLenz59) of @USC talks on addressing resistance to ICIs in colorectal cancer

Watch: 👉http://ow.ly/12oo50MIP1g👈

@ASCO #GI23 #GastrointestinalCancer #CRCSM #ColorectalCancer

Reply on Twitter 1622520898484830208Retweet on Twitter 1622520898484830208Like on Twitter 16225208984848302082Twitter 1622520898484830208
Load More
Prostate Cancer Bladder Cancer Kidney Cancer

Latest videos

View all
3:07
PROpel: olaparib plus abiraterone as 1L treatment for metastatic CRPC
Fred Saad • 17 Feb 2022
1:35
ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC
Andrew Armstrong • 17 Feb 2022
1:34
Combination therapies for the treatment of prostate cancer
Fred Saad • 17 Feb 2022
1:19
An AI biomarker to aid in the decision of treatment with ADT for localized prostate cancer
Andrew Armstrong • 17 Feb 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals